The global market for contract manufacturing of oral solid dosage forms is projected to grow significantly in the coming years, driven by several key factors. In 2023, this market was valued at $36.50 billion and is anticipated to expand at a compound annual growth rate (CAGR) of 5.97% from 2024 to 2030.

Several factors contribute to this growth. Firstly, advancements in drug delivery technology, such as targeted drug delivery and sustained release dosage forms, are increasing the demand for complex oral solid dosage forms. Secondly, contract development and manufacturing organizations (CDMOs) are investing heavily in expanding their oral solid dosage development capabilities. Thirdly, the growing demand for novel therapies is driving the need for specialized manufacturing processes. 

Gather more insights about the market drivers, restrains and growth of the Oral Solid Dosage Contract Manufacturing Market 

Additionally, the pharmaceutical industry is constantly evolving, and oral pharmaceutical products may soon be replaced by newer technologies. For instance, the integration of 3D printing in oral solid dosage manufacturing offers precise control over drug release and enables customization of dosage forms based on individual patient needs. This technology allows for the production of complex shapes and formulations, providing greater flexibility in drug design and manufacturing.

Furthermore, advancements in controlled-release technologies are improving drug delivery by providing sustained- and extended-release options. This enhances therapeutic efficacy and patient compliance. The adoption of digital technologies and data analytics in oral solid dosage manufacturing is also driving growth. Contract manufacturers leveraging these technologies can provide transparent and data-driven solutions, improving process monitoring, quality control, and overall efficiency.

Mechanism Segmentation Insights

Controlled Release Segment

In 2023, the controlled release (CR) segment held a significant market share of 52.2%. This drug delivery mechanism is designed to maintain a steady drug concentration in the body over an extended period. Recent innovations in oral CR delivery systems, such as intestinal patches, polymer nanosystems, dome tablets, dual drug tablets, and bioinspired approaches like exosomes, have significantly advanced this field.

Immediate Release Segment

The immediate release (IR) segment is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.85%. IR dosage forms, often referred to as conventional release dosage forms, enable rapid drug absorption after oral administration. Some IR formulations are designed as dispersible dosage forms, intended to dissolve or disintegrate before ingestion. Among various dosage forms, IR formulations are the most widely used in the pharmaceutical market due to their ability to provide rapid therapeutic effects. 

Order a free sample PDF of the Oral Solid Dosage Contract Manufacturing Market Intelligence Study, published by Grand View Research.